Skip to main content

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The FRACTION-RCC study

Toni Choueiri reports preliminary results from the FRACTION-RCC study showing encouraging efficacy of nivolumab plus ipilimumab in advanced renal cell carcinoma patients who have progressed on prior immunotherapy (3:11).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Read transcript